User: Guest  Login
Title:

Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.

Document type:
Article; Journal Article
Author(s):
Straka, Christian; Salwender, Hans; Knop, Stefan; Vogel, Martin; Müller, Jürgen; Metzner, Bernd; Langer, Christian; Sayer, Herbert; Jung, Wolfram; Dürk, Heinz A; Bassermann, Florian; Gramatzki, Martin; Rösler, Wolf; Wolf, Hans-Heinrich; Brugger, Wolfram; Engelhardt, Monika; Fischer, Thomas; Liebisch, Peter; Einsele, Hermann
Abstract:
OBJECTIVE: A post hoc subgroup analysis of two phase III trials (NCT00416273, NCT00416208) was carried out to investigate the influence of 100/140 and 200 mg/m² melphalan as well as single/double autologous stem cell transplantation (ASCT) on progression-free survival (PFS). Additionally, the effect of bortezomib consolidation on PFS was analyzed. METHODS: Following induction therapy and high-dose melphalan with subsequent ASCT, patients with newly diagnosed multiple myeloma (NDMM) were randomiz...     »
Journal title abbreviation:
Eur J Haematol
Year:
2021
Journal volume:
107
Journal issue:
5
Pages contribution:
529-542
Fulltext / DOI:
doi:10.1111/ejh.13690
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/34270825
Print-ISSN:
0902-4441
TUM Institution:
290; 679; III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX